Meeting
2024 ASCO Annual Meeting
Development of an mRNA therapeutic vaccine for virally driven Merkel cell carcinoma.
Authors
Alexander Frey
Yale School of Medicine, New Haven, CT
Alexander Frey , Curtis Perry , Kelly Olino , Jeffrey Joseph Ishizuka
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Vaccines
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 2637)
DOI
10.1200/JCO.2024.42.16_suppl.2637
Abstract #
2637
Poster Bd #
116
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
The impact of COVID-19 mRNA vaccines on immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors.
First Author: Mengni Guo
Poster
2022 ASCO Annual Meeting
Personalized neoantigen DNA vaccines expand tumor-specific T cells in the periphery which infiltrate the tumor in hepatocellular carcinoma.
First Author: Renzo Perales
Poster
2018 ASCO Annual Meeting
Phase 1/2 study of mRNA vaccine therapy + durvalumab (durva) ± tremelimumab (treme) in patients with metastatic non-small cell lung cancer (NSCLC).
First Author: Leena Gandhi
First Author: Hiroshi Kagamu